Inovio Pharmaceuticals, Inc. Closes $87.4 Million Underwritten Financing

PLYMOUTH MEETING, Pa., May 5, 2015 – (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (Nasdaq:INO) (“Inovio” or the “Company”), today closed its previously announced underwritten public offering of 10,925,000 shares of the Company’s common stock, including 1,425,000 shares of common stock issued pursuant to the underwriter’s exercise of its option, at the public offering price of $8.00 per share. The gross proceeds of this offering were $87.4 million. Net proceeds to the Company, after deducting the underwriter’s discounts and commission and other estimated offering expenses payable by the Company, were approximately $82.1 million.

Maxim Group acted as a co-manager for Inovio’s $87.4 million follow-on offering.


This entry was posted in Investment Banking News: Q2- 2015. Bookmark the permalink.